Ad-hoc | 17 December 2002 07:00

Carl Zeiss Meditec AG english

Carl Zeiss Meditec: Sales up by six percent Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Carl Zeiss Meditec: Sales up by six percent Operative business well placed for further growth: cash-flow and equity ratio significantly higher – liquidity tripled – integration-related costs temporarily influencing result Jena, 17 December 2002. Carl Zeiss Meditec AG has presented its first annual statement (30 September 2002) since the merger. Group sales rose by 6% to EUR 204.6 million (previous year: EUR 193.3 million). The group therefore performed well in a difficult economic climate. The integration has set the course for the company’s further growth. The operating result (EBIT) was still burdened by the costs arising from integration. Nevertheless, the EBIT figure came in at EUR 8.4 million, after EUR 13.7 million the year before. However, the 2001/2002 statement is only comparable to that of the previous year to a limited extent. According to US GAAP the business of the former Asclepion was only consolidated from the start of July 2002. There is now a firm basis for further growth: cash-flow from operating activities rose significantly in the financial year ended to EUR 22.7 million (previous year: EUR 0.9 million). Liquid funds more than tripled – from EUR 2.1 million the previous year to EUR 7.2 million this year. The equity ratio rose to 49%, up from 23% last year. Contact Carl Zeiss Meditec AG Jens Brajer/Director Investor Relations Goeschwitzer Strasse 51 – 52, 07745 Jena/Germany Tel.: + 49 (3641) 220-105 Fax: + 49 (3641) 220-102 E-Mail: investors@meditec.zeiss.com end of ad-hoc-announcement (c)DGAP 17.12.2002 ——————————————————————————– WKN: 531370; ISIN: DE0005313704; Index: Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München und Stuttgart 170700 Dez 02